Osiris Announces Enrollment of Patients in a Clinical Trial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
92
Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers

COLUMBIA, Md., July 11, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced the initiation of its “Multicenter, Prospective, Randomized, Open-Label Study with a Crossover Extension Option to Evaluate the Safety and Efficacy of GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers.”

This study is expected to enroll up to 200 patients in approximately 30 clinical sites. Patients will be randomized 1:1 to receive GrafixPL PRIME plus standard compression therapy (SOC) versus SOC alone in patients with chronic venous leg ulcers (VLUs). The study objective is to evaluate the safety and efficacy of weekly applications of GrafixPL PRIME plus SOC versus SOC alone for chronic VLUs with a size between 1 cm 2 and 25 cm 2 . Patients in the SOC alone group whose ulcers do not close will be offered GrafixPL PRIME adjunct to SOC in a crossover extension treatment phase of up to 12 treatments. 

Osiris Therapeutics is partnering with CPC Clinical Research, an Academic Clinical Research Organization (ARO), who will be responsible for clinical site monitoring, all data management, and pharmacovigilance and biostatistical services.

The study protocol has been designed using the FDA guidelines for Industry clinical trials for products used to treat burns and cutaneous ulcers (Guidance for Industry, 2006). The primary efficacy endpoint of the study is complete ulcer closure by week 12.  The primary endpoint will undergo confirmation by blinded evaluators at the Wound Core Lab at CPC Clinical Research.  

About Venous Leg Ulcers Venous Leg Ulcers (VLUs) constitute more than half of lower leg ulcerations, with an overall prevalence that ranges from 0.06% to 2%. 1 The prognosis of these ulcers is very poor, with only 50% of ulcers reportedly achieving closure after four months of treatment. 2 In many cases VLUs can remain open even after years of treatment; for example 20% of ulcers remained open after two years and 8% of ulcers after eight years. 2 Treatment of those chronic VLUs remains a challenging problem for wound care providers.  Chronic VLUs have a major negative impact on a patient’s quality of life and are associated with more than $18B annual cost of care. 3

About Prestige Lyotechnology SM (PL) and GrafixPL PRIME GrafixPL PRIME is processed using Prestige Lyotechnology, which is Osiris’ novel proprietary preservation technique for ambient storage of living tissues.  It is flexible and conforming and designed as a wound cover/barrier for application directly to hard-to-treat acute and chronic wounds, including but not limited to diabetic foot ulcers, venous leg ulcers and thermal burns. The structural matrix, growth factors, and cell viability of GrafixPL PRIME are equivalent to that of Grafix PRIME, a cryopreserved placental membrane, but without the constraints of ultra-low temperature storage.

About Osiris Therapeutics Osiris Therapeutics, Inc., based in Columbia, Maryland, researches, develops, manufactures and commercializes regenerative medicine products intended to improve the health and lives of patients and lower overall healthcare costs. We have achieved commercial success with products in orthopedics, sports medicine and wound care, including the Grafix product line, Stravix®, BIO 4® and Cartiform®. We continue to advance our research and development by focusing on innovation in regenerative medicine, including the development of bioengineered stem cell and tissue‑based products. Osiris®, Grafix®, GrafixPL®, GrafixPL PRIME ™ Cartiform®, Prestige sm and Prestige Lyotechnology sm are our trademarks. BIO 4 ® is a trademark of Howmedica Osteonics Corp., a subsidiary of Stryker Corporation. More information can be found on the Company’s website, www.Osiris.com . (OSIR-G)

About CPC Clinical Research CPC Clinical Research is an academically led clinical research organization who has responded to the demands of a fast-paced clinical research industry and competitive market for over 25 years. CPC offers full service clinical trial design, oversight, and management with rapid access to Key Opinion Leaders in a variety of therapeutic areas. Many of CPC’s leadership team have chaired and/or served on FDA advisory committees including the Cardiovascular and Renal, Endocrine and Metabolism, and Reproductive Health committees. www.cpcmed.org

Forward-Looking Statements Statements herein relating to the future of Osiris Therapeutics, Inc. and the ongoing research and development of our products are forward-looking statements. Osiris Therapeutics, Inc. cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Osiris Therapeutics Inc. Annual Report on Form 10-K for the years ended December 31, 2017, 2016 and 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2018,  as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Examples of forward-looking statements may include, without limitation, statements regarding the anticipated efficiencies and advantages of products and the likelihood of customer clinical adoption of any new products. Although well characterized in scientific literature and studies, preservation of tissue integrity, including cells, may not be indicative of clinical outcome.  Accordingly, you should not unduly rely on these forward-looking statements. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

For additional information, please contact:

 Diane Savoie Osiris Therapeutics, Inc. (443) 545-1834 OsirisPR@Osiris.com

  1. Valencia IC, Falabella A, Kirsner RS, et al. Chronic venous insufficiency and venous leg ulceration. J Am Acad Dermatol. 2001; 44: 401-421.
  2. Simka M, Majewski E. The social and economic burden of venous leg ulcers: focus on the role of micronized purified flavonoid fraction adjuvant therapy. Am J Clin Dermatol. 2003; 4: 573-581.
  3. Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N. Medical, drug, and work-loss costs of venous leg ulcers. Value Health 2013; 16: A73.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Minno Bets on Listener Kids to Build Premium Growth

Updated Category News Views 38

Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 179

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 21

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 53

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
OFRM Recall Leaves Investors Facing Hard Questions

Updated Category News Views 60

Nothing wrecks a young consumer brand’s glow faster than a recall involving toddlers, and Once Upon A Farm has just learned that lesson in the ugliest possible way. On November 2, 2026, shares of NYSE:OFRM fell 37% to close at $9.44. That left the stock roughly 47% below its $18 IPO price. Those are not the garden-variety bruises of a weak quarter. That is the market...

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 156

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
Gildan Lawsuit Puts Revenue Controls Under a Harsh Light

Updated Category News Views 61

Receivables have a nasty way of becoming everybody’s problem once the story cracks. Gildan Activewear is staring at that uncomfortable reality after a securities fraud class action was filed on behalf of investors who bought or acquired shares between February 19, 2025 and June 15, 2026. The case, Cortez v. Gildan Activewear Inc., is pending in the U.S. District Court...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 80

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 113

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 87

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading

Top 5 Most Recently Viewed Articles

Gen Z's Evolving College Search: The Impact of Politics

Updated Category News Views 205

Understanding Gen Z's College Decisions In recent times, higher education choices have become a significant reflection of societal shifts, especially concerning political climates. A new report from an education company highlights how politics influence college decisions among Gen Z students. This demographic, characterized as more conscious of political environments,...

Continue Reading
LiveWire and KYMCO Unveil Electric Maxi-Scooter Plans

Updated Category News Views 46

LiveWire and KYMCO Strengthen Partnership LiveWire, a prominent figure in the electric motorcycle industry, has exciting news to share. In collaboration with KYMCO, a highly regarded powersports manufacturer, the two companies are working to amplify their strategic alliance. This partnership focuses on introducing an electric maxi-scooter tailored specifically for the...

Continue Reading
Rudholm Group's Compliance Portal: Regulatory Game Changer or Just Noise?

Updated Category News Views 180

Rudholm Group just unveiled its new Compliance Portal on February 18, 2026, aiming to tackle the labyrinth of ever-evolving regulations in the apparel sector. You know how it is—every corner of this industry is drowning in red tape, and brands are gasping for air trying to keep up with local laws that change faster than a fashion trend. The CEO, Dennis Lau, stated they...

Continue Reading
Teva's Upcoming Conference Call for Q4 Financial Results

Updated Category News Views 74

Teva's Upcoming Conference Call for Q4 Financial Results TEL AVIV, Israel — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced an important event for investors and stakeholders. The company plans to release its fourth quarter 2025 financial results on a specific date. Following the release, Teva will host a conference call and a live webcast to...

Continue Reading
Understanding the Recent Decline of Moderna's Stock and Future Prospects

Updated Category News Views 178

Moderna's Stock Takes a Dive: Key Factors Explained Moderna Inc (NASDAQ: MRNA) has faced a significant drop in its stock value recently, prompting investors to seek clarity on the reasons behind this decline. The company has been in the news with some critical developments that have overshadowed its achievements in the medical field. Recent Clinical Setbacks The primary...

Continue Reading